Drug lookup
Drug reference

drotaverine

PDE-4 inhibitor, Non-anticholinergic smooth muscle antispasmodic · Antispasmodic

PDE-4 inhibitor, Non-anticholinergic smooth muscle antispasmodicAntispasmodic
CDSCO approved
EXCRETION
not curated
INTERACTIONS
none in our sources
PREGNANCY
not curated

Mechanism

Drotaverine is a novel non-anticholinergic smooth muscle antispasmodic which acts by inhibiting phosphodiesterase-4 (PDE-4) selectively for smooth muscle. This leads to elevation of intracellular cAMP/cGMP, attending smooth muscle relaxation. Changes in membrane ionic fluxes and membrane potential have also been shown.

Indications

Intestinal colicBiliary colicRenal colicIrritable bowel syndromeUterine spasms

Dosing

Adult
40–80 mg TDS oral; 40 mg/2 ml inj.

Side effects

Common
HeadacheDizzinessConstipationFlushing
Serious
  • Fall in BP (can occur on i.v. injection)

Drug interactions

Levodopa
Moderate
Database

Reduced anti-parkinsonian effect of levodopa, worsening of tremor and rigidity.

Avoid concomitant use. If unavoidable, monitor for reduced efficacy of levodopa and consider dose adjustment of levodopa.

Antihypertensives (e.g., Ace Inhibitors, Arbs, Diuretics)
Mild
Database

Increased risk of orthostatic hypotension, dizziness, and syncope.

Monitor blood pressure, especially during initiation or dose changes. Advise patients to stand up slowly.

Benzodiazepines
Mild
Database

Increased sedation, dizziness, and impaired psychomotor function.

Advise caution when driving or operating machinery. Monitor for excessive sedation.

Opioid Analgesics
Mild
Database

Increased sedation, dizziness, and impaired psychomotor function.

Advise caution when driving or operating machinery. Monitor for excessive sedation.

Tricyclic Antidepressants (tcas)
Mild
Database

Increased risk of anticholinergic side effects such as dry mouth, constipation, urinary retention, and blurred vision.

Monitor for increased anticholinergic side effects. Consider alternative antispasmodics if these effects are bothersome.

Related guidelines

Ask House about drotaverine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team